2,1,3-苯并恶二唑-4-甲酰胺 | 408502-46-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶二唑类
• 中文名称: 2,1,3-苯并恶二唑-4-甲酰胺
• 英文名称: 4-benzofurazanylcarboxamide
• 英文别名: 2,1,3-Benzoxadiazole-4-carboxamide
• CAS: 408502-46-5
• 化学式: C₇H₅N₃O₂
• mdl: MFCD18811779
• 分子量: 163.136
• InChiKey: FMOKHNPUXVSZTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  82
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  benzofurazan-4-carboxylic acid methyl ester 在 氨 作用下， 以 甲醇 为溶剂， 以53%的产率得到2,1,3-苯并恶二唑-4-甲酰胺
  参考文献：
  名称：

  Nitroanilines are the reduction products of benzofuroxan system by oxyhemoglobin (HbO22+)

  摘要：

  Benzofuroxans are interesting compounds which display several biochemical and pharmacological properties. Recent studies from our laboratory demonstrate that they are reduced by ferrous salts at room temperature and that the principal reaction products are o-nitroanilines. This paper shows that simple benzofuroxan derivatives are also able to oxidise HbO(2)(2+) to methemoglobin (MetHb(3+)) (UV detection) and to form o-nitroanilines (HPLC detection). From a toxicological point of view this reaction is interesting, since it indicates that the blood is a site for metabolism of these compounds with consequent methemoglobinemia and formation of toxic compounds. (C) 2001 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(01)01139-9

文献信息

• [EN] BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY<br/>[FR] COMPOSES A BASE DE BENZOFURAZAN RENFORÇANT L'ACTIVITE DU RECEPTEUR DE L'AMPA
  申请人：CORTEX PHARMACEUTICALS, INC.

  公开号：WO1998035950A1

  公开（公告）日：1998-08-20

  (EN) Compounds of general structural formula (I) are shown to have AMPA receptor enhancing properties. The compounds are useful for such therapeutic purposes as facilitating the learning of behaviors dependent upon AMPA receptors, and in treating conditions, such as memory impairment, in which AMPA receptors, or synapses utilizing these receptors, are reduced in numbers or efficiency. They may also be used to enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior.(FR) La présente invention concerne des composés représentés par la formule structurelle générale (I) et qui font preuve d'une aptitude à renforcer l'activité du récepteur AMPA. Ces composés conviennent à des fins thérapeutiques et notamment pour l'apprentissage de comportements liés aux récepteurs de l'AMPA, et pour le traitement d'états tels que les déficiences de la mémoire dans lesquelles les récepteurs de l'AMPA, ou les synapses utilisant ces récepteurs, sont présents en nombre réduit ou font preuve d'une moindre efficacité. Ces composés permettent également d'augmenter l'activité excitatrice des synapses afin de rétablir un équilibre entre les sous-régions du cerveau, comme dans le cas du traitement de la schizophrénie ou des comportements schizophréniformes.

  (中) 通用结构式（I）的化合物被证明具有增强AMPA受体的性质。这些化合物可用于促进依赖于AMPA受体的行为的学习，以及治疗AMP受体数量或效率降低的病症，例如记忆障碍。它们还可以用于增强兴奋性突触活动，以恢复大脑亚区之间的平衡，例如治疗精神分裂症或类精神分裂行为。
• Benzofurazan compounds which enhance AMPA receptor activity
  申请人：Cortex Pharmaceuticals, Inc.

  公开号：US20020055508A1

  公开（公告）日：2002-05-09

  Compounds of general structural formula (1) are shown to have AMPA receptor enhancing properties. The compounds are useful for such therapeutic purposes as facilitating the learning of behaviors dependent upon AMPA receptors, and in treating conditions, such as memory impairment, in which AMPA receptors, or synapses utilizing these receptors, are reduced in numbers or efficiency. They may also be used to enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. 1

  通用结构式（1）的化合物被证明具有增强AMPA受体的性质。这些化合物可用于促进依赖于AMPA受体的行为的学习，并用于治疗存在AMPA受体或利用这些受体的突触数量或效率减少的情况，例如记忆障碍。它们也可以用于增强兴奋性突触活动，以恢复大脑亚区之间的不平衡，如治疗精神分裂症或类精神分裂行为。1
• Benzofurazan compounds for enhancing glutamatergic synaptic responses
  申请人：The Regents of the University of California

  公开号：US20020055498A1

  公开（公告）日：2002-05-09

  Compounds of the general structural formula 1 are shown to have AMPA receptor enhancing properties. The compounds are useful for such therapeutic purposes as facilitating the learning of behaviors dependent upon AMPA receptors, and in treating conditions, such as memory impairment, in which AMPA receptors, or synapses utilizing these receptors, are reduced in numbers or efficiency. They may also be used to enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior.

  具有一般结构式1的化合物被证明具有增强AMPA受体的性质。这些化合物可用于促进依赖于AMPA受体的行为的学习，以及治疗AMP受体数量或效率降低的情况，例如记忆障碍。它们还可以用于增强兴奋性突触活动，以恢复大脑亚区之间的平衡，如治疗精神分裂症或类精神分裂行为。
• BENZOFURAZAN DERIVATIVES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES
  申请人：The Regents of the University of California

  公开号：EP1428534A1

  公开（公告）日：2004-06-16

  Compounds of the general structural formula are shown to have AMPA receptor enhancing properties. The compounds are useful for such therapeutic purposes as facilitating the learning of behaviors dependent upon AMPA receptors, and in treating conditions, such as memory impairment, in which AMPA receptors, or synapses utilizing these receptors, are reduced in numbers or efficiency. They may also be used to enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior.

  一般结构式为 具有增强 AMPA 受体的特性。这些化合物可用于以下治疗目的：促进依赖 AMPA 受体的行为学习；治疗 AMPA 受体或利用这些受体的突触数量减少或效率降低的疾病，如记忆损伤。它们还可用于增强兴奋性突触活动，以恢复大脑亚区域之间的不平衡，如治疗精神分裂症或精神分裂症状行为。
• Hydrogel comprising cells for local release of growth factors to mediate motor recovery after stroke
  申请人：The Regents of the University of California

  公开号：EP2801377A1

  公开（公告）日：2014-11-12

  Methods of improving recovery of a mammal after an ischemic event (e.g., stroke) are provided. In various embodiments the methods involve administering a neural growth factor (e.g., BDNF) into the infarct (e.g., stroke) cavity in a biocompatible hydrogel formulation. In certain embodiments the hydrogel comprises a thiolated hyaluronan and a thiolated gelatin with an optional thiolated heparin.

  本文提供了改善缺血性事件（如中风）后哺乳动物恢复的方法。在不同的实施方案中，这些方法包括在生物相容性水凝胶配方中将神经生长因子（如 BDNF）注入梗塞（如中风）腔。在某些实施方案中，水凝胶包括硫醇化透明质酸和硫醇化明胶以及任选的硫醇化肝素。